11 HRT Myths That Grew From the Women's Health Initiative That Scientists Have Since Corrected — and What Women Deserve to Know Now
There is something quietly infuriating about learning that the fear driving a decision — one that affected years of your life — was based on a misreading of data that researchers identified and began correcting almost immediately. Women who asked about HRT in the 2000s and 2010s and were turned away deserved better information than they got. This article exists because that debt is still outstanding.
Learn more about Rose →Myth: HRT significantly increases every woman's risk of breast cancer
The WHI reported a relative risk increase for breast cancer that was widely communicated as alarming, but the absolute risk increase for combined estrogen-progestogen therapy was approximately 8 additional cases per 10,000 women per year — a figure smaller than the risk associated with drinking one alcoholic drink per day or being overweight. Crucially, women taking estrogen-only therapy (those who had had a hysterectomy) actually showed a reduced risk of breast cancer in long-term follow-up data. The risk profile also varies substantially depending on the type of progestogen used, with body-identical micronised progesterone appearing significantly safer than the synthetic medroxyprogesterone acetate used in the original WHI.
Myth: The WHI studied women who were representative of those seeking HRT
The average age of participants in the WHI was 63, and more than 70% of the women enrolled were over 60 — a full decade or more older than most women who begin hormone therapy around the time of menopause. Many participants had pre-existing cardiovascular disease or risk factors, meaning the study was, in effect, testing the impact of introducing hormones into an already-changed physiological environment. Applying findings from this population to healthy women in their late 40s or early 50s seeking symptom relief is a scientific category error that researchers have repeatedly flagged.
Myth: HRT causes heart disease
The WHI found elevated cardiovascular risk in older women starting HRT, but subsequent analysis revealed this was largely confined to women who began therapy more than ten years after menopause — a finding now described as the 'timing hypothesis' or 'window of opportunity.' Women who start HRT within ten years of menopause onset, or before age 60, show either neutral or beneficial cardiovascular outcomes in both observational data and reanalysis of trial data. The underlying mechanism is well understood: estrogen has protective effects on arterial walls that are diminished once atherosclerotic change has already begun.
Myth: There is a safe five-year limit on HRT use
The arbitrary five-year rule that became widespread clinical practice after 2002 has no strong evidence base; it was essentially a precautionary default rather than a conclusion drawn from data. Major professional bodies including the British Menopause Society, the Menopause Society (formerly NAMS), and the International Menopause Society have since stated that duration of HRT use should be based on individual assessment of benefits and risks, not a fixed time limit. For many women, particularly those with significant symptoms or bone density concerns, the benefits of longer-term use outweigh the risks.
Myth: All HRT is the same
The WHI used oral conjugated equine estrogen combined with medroxyprogesterone acetate — a specific formulation that bears little resemblance to the transdermal estradiol and micronised progesterone now widely prescribed in many countries. Transdermal delivery bypasses first-pass liver metabolism, which eliminates the increased blood clot risk observed with oral estrogen; this is not a minor distinction, as VTE (venous thromboembolism) risk with transdermal HRT appears to be no higher than baseline. The body of evidence now firmly supports treating different HRT formulations as having meaningfully different risk and benefit profiles.
Myth: HRT increases the risk of blood clots for everyone
Oral estrogen does carry an elevated VTE risk because it raises clotting factors during hepatic processing — this is real and should not be dismissed. However, transdermal estradiol delivered through patches, gels, or sprays does not appear to carry this same elevated risk, and multiple large observational studies and meta-analyses have confirmed this distinction. Women with a personal or family history of clotting disorders are not automatically excluded from HRT consideration when transdermal routes are used, though individual medical assessment remains essential.
Myth: HRT increases stroke risk meaningfully in healthy younger women
The WHI found a statistically significant increase in stroke risk, but again this was in an older population using oral therapy, and the absolute numbers were small. Reanalysis stratified by age showed no significant increase in stroke risk in women aged 50–59 at study entry. Transdermal estrogen, which avoids the hepatic changes that affect blood pressure regulation and coagulation, is not associated with increased stroke risk in the evidence base available for healthy women beginning HRT at or near the time of natural menopause.
Myth: The cognitive decline findings from the WHI settled the question of HRT and dementia
The WHI Memory Study (WHIMS), which found increased dementia risk in women over 65 using combined HRT, has been extensively critiqued for the same fundamental flaw as the parent trial: participants were elderly and years past menopause. The critical period hypothesis for brain health — which proposes that estrogen is neuroprotective only when introduced during a sensitive window around menopause — is supported by a growing body of neuroimaging, biomarker, and observational research. Starting HRT in older women who have been estrogen-depleted for a decade does not replicate the effect of maintaining hormonal support through the transition itself.
Myth: Bone protection from HRT disappears when you stop
HRT does unambiguously protect bone density while it is being taken, and the WHI itself confirmed reductions in hip and vertebral fracture rates — one of the few findings from the trial that was unambiguously positive. The question of what happens to bone after stopping HRT is more nuanced than early messaging suggested; bone loss does accelerate after cessation, but the fracture protection gained during years of use does not evaporate instantly, and longer duration of use appears to have lasting benefits. This makes early initiation and adequate duration particularly relevant for women with risk factors for osteoporosis.
Myth: Women with a family history of breast cancer cannot consider HRT
Family history of breast cancer is a risk factor that requires honest, individualised discussion — not an automatic disqualification from HRT. Many women with family history have lower absolute risks than they assume, and the interaction between HRT and genetic predisposition (including BRCA variants) requires specialist input rather than a blanket prohibition. For women with severe menopausal symptoms, untreated menopause also carries its own health risks, including cardiovascular disease and osteoporosis, and the quality-of-life cost of severe untreated symptoms is itself a health outcome that deserves weight in the risk-benefit conversation.
Myth: The science has been 'mixed' — there is no clear expert consensus now
Post-WHI, the narrative that hormone therapy was simply 'controversial' took hold and has been used to justify clinical inaction ever since, but this framing no longer reflects the state of expert opinion. The British Menopause Society, the Menopause Society, the European Menopause and Andropause Society, and many national endocrine bodies have published guidance affirming that HRT is appropriate and beneficial for the majority of healthy women under 60 with significant menopausal symptoms, and that the risks for this population were overstated by the original WHI interpretation. What remains genuinely variable is not the broad consensus but the degree to which that consensus has filtered into the average general practice appointment.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.